CALR and in situ carcinoma: Immunostaining for CALR was more evident in the GLLP group on both PND 21 (Figure 10C and 10D) and PND 540 (Figure 10G, 10H) compared to the CTR group (Figure 10A, 10B, 10E, 10F) mainly in areas of carcinoma in situ.